Wegovy for NASH: Off-Label Evidence, Risks, and Clinical Tradeoffs

What NASH Is and Why Semaglutide Entered the Conversation

NASH is a progressive form of nonalcoholic fatty liver disease (NAFLD) defined by hepatic steatosis plus lobular inflammation and hepatocyte ballooning on biopsy. It affects an estimated 1.5% to 6.5% of the U.S. adult population, with prevalence climbing sharply among people with obesity and type 2 diabetes [1]. Left untreated, NASH can progress to cirrhosis, hepatocellular carcinoma, and liver failure.

For decades, the standard recommendation was weight loss through lifestyle modification. A 2015 prospective study demonstrated that losing ≥10% of body weight resolved NASH in 90% of participants and improved fibrosis in 45% [2]. The problem: fewer than 10% of patients in clinical practice sustain that degree of weight loss with diet and exercise alone. GLP-1 receptor agonists like semaglutide produce significant weight reductions (14.9% mean loss in the STEP-1 trial, N=1,961, at 68 weeks) [3], which prompted researchers to test whether these drugs could treat NASH directly. Semaglutide also reduces hepatic de novo lipogenesis and lowers markers of systemic inflammation, both of which are mechanistically relevant to NASH pathology [4].

The nomenclature shifted in 2023 when a multi-society consensus renamed NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD) and NASH to metabolic dysfunction-associated steatohepatitis (MASH) [5]. Both terms appear in current literature. This article uses "NASH" because that is the term most patients search for and the term used in the primary trial data.

The Phase 2 Trial: What Semaglutide Actually Showed in NASH

The strongest direct evidence comes from Newsome et al., published in the New England Journal of Medicine in 2021 [6]. This was a 72-week, double-blind, placebo-controlled, phase 2 trial enrolling 320 patients with biopsy-confirmed NASH and liver fibrosis stage F1, F2, or F3.

Patients received daily subcutaneous semaglutide at 0.1 mg, 0.2 mg, or 0.4 mg, or placebo. The primary endpoint was NASH resolution without worsening of fibrosis. Results for the 0.4 mg daily group: 59% achieved NASH resolution versus 17% on placebo (P<0.001). That is a 42-percentage-point absolute difference.

A critical detail often missed: the secondary endpoint of fibrosis improvement by ≥1 stage without worsening of NASH did not reach statistical significance. In the 0.4 mg group, 43% showed fibrosis improvement versus 33% on placebo (P=0.48) [6]. NASH resolution is meaningful, but fibrosis stage is the strongest predictor of liver-related mortality [7]. The disconnect between these two endpoints is the central limitation of the current evidence base.

The trial used daily subcutaneous dosing (0.4 mg/day), not the weekly 2.4 mg Wegovy formulation. While total weekly semaglutide exposure is roughly comparable (0.4 mg × 7 = 2.8 mg/week vs. 2.4 mg/week), pharmacokinetic profiles differ between daily and weekly dosing. No published trial has tested Wegovy's exact 2.4 mg once-weekly formulation specifically in a NASH population with biopsy endpoints.

Off-Label Status: What FDA Approval Actually Covers

Wegovy received FDA approval in June 2021 for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia [8]. The label does not include NASH, MASH, NAFLD, or any liver-related indication.

Off-label prescribing is legal. Physicians may prescribe any FDA-approved drug for a non-approved indication based on clinical judgment. A 2019 analysis found that approximately 20% of all outpatient prescriptions in the United States are off-label [9]. The practice is common, but "legal" does not mean "supported by the same evidence threshold as an approved indication."

For NASH specifically, the American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance notes that GLP-1 receptor agonists may be considered in patients with NASH and coexisting type 2 diabetes or obesity, but stops short of a broad recommendation for NASH treatment independent of these comorbidities [10]. The guidance does not name Wegovy or semaglutide 2.4 mg specifically for NASH.

Risks of Using Wegovy Off-Label for NASH

Gastrointestinal adverse events are the most common concern. In the STEP-1 weight management trial, 44.2% of semaglutide-treated patients reported nausea, 31.5% reported diarrhea, and 24.8% reported vomiting [3]. These rates are generally consistent across semaglutide trials. Most GI symptoms are transient and peak during dose escalation, but roughly 7% of patients in STEP-1 discontinued treatment due to GI intolerance.

Pancreatitis remains a labeled risk. GLP-1 receptor agonists carry a class warning for acute pancreatitis based on post-marketing reports. The absolute incidence is low (estimated at 1 to 2 cases per 1,000 patient-years based on pooled GLP-1 RA data), but patients with NASH often have metabolic risk factors that independently raise pancreatitis risk, including hypertriglyceridemia and gallstone disease [11].

Gallbladder events deserve specific attention. In the STEP trials, cholelithiasis occurred in 1.6% of semaglutide-treated patients versus 0.7% on placebo. Rapid weight loss itself promotes gallstone formation by increasing biliary cholesterol saturation [12]. NASH patients who are already at elevated risk for gallbladder disease face compounded exposure.

Lean NASH patients present a distinct concern. Roughly 10% to 20% of NASH cases occur in individuals with a BMI <25 kg/m² [13]. For these patients, Wegovy's weight-loss mechanism may cause clinically undesirable muscle and fat loss without a clear liver benefit, since the phase 2 trial predominantly enrolled patients with obesity.

Dr. Rohit Loomba, director of the MASLD Research Center at UC San Diego, has noted: "Semaglutide's liver effects are promising, but we need phase 3 biopsy data before we can confidently separate the direct hepatic benefit from the indirect benefit of weight loss" [14].

Insurance, Cost, and Access Barriers

Wegovy's list price is approximately $1,349 per month without insurance. Most commercial insurers and Medicare Part D plans cover Wegovy only for the FDA-approved weight management indication. Off-label use for NASH is almost universally denied on prior authorization review.

Some clinicians prescribe Wegovy for weight management in patients who also have NASH, effectively using the approved indication as the billing rationale when the patient qualifies by BMI criteria. This is legally and ethically defensible when the patient genuinely meets weight management criteria. It does not apply to lean NASH patients or those with BMI <27 without a weight-related comorbidity.

An alternative pathway: Ozempic (semaglutide 1 mg or 2 mg) is FDA-approved for type 2 diabetes. NASH patients with concurrent type 2 diabetes may obtain insurance coverage for Ozempic more easily, though the maximum approved Ozempic dose (2 mg/week) is lower than Wegovy's 2.4 mg. The AASLD guidance acknowledges GLP-1 RAs in the context of type 2 diabetes and NASH overlap but does not endorse dose escalation beyond approved ranges for liver-specific benefit [10].

How Wegovy Compares to FDA-Approved NASH Treatment

Resmetirom (brand name Rezdiffra) received FDA accelerated approval in March 2024 as the first drug specifically approved for MASH with moderate-to-advanced hepatic fibrosis (stage F2 or F3), in combination with diet and exercise [15]. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg daily achieved MASH resolution without worsening fibrosis in 30% of patients versus 10% on placebo at 52 weeks. Fibrosis improvement by ≥1 stage occurred in 26% versus 14% on placebo [16].

Comparing the two drugs head-to-head requires caution. Trial populations, endpoints, and durations differ substantially. Semaglutide's 59% NASH resolution rate in the phase 2 trial appears higher than resmetirom's 30%, but the semaglutide trial was 72 weeks versus 52, used a daily subcutaneous injection versus an oral tablet, and enrolled a different fibrosis distribution. Resmetirom demonstrated a statistically significant fibrosis benefit that semaglutide's phase 2 trial did not.

Dr. Arun Sanyal, a hepatologist at Virginia Commonwealth University and principal investigator on multiple NASH trials, has stated: "The ideal future approach to MASH may involve combination therapy targeting complementary pathways. A GLP-1 agonist addressing metabolic drivers alongside a thyroid hormone receptor-beta agonist like resmetirom targeting intrahepatic lipid metabolism is a plausible combination" [17].

For clinicians deciding between these options today, the distinction is straightforward: resmetirom has an FDA-approved liver indication with confirmed fibrosis benefit. Semaglutide does not. The evidence for semaglutide in NASH is real but incomplete.

The ESSENCE Trial: What Phase 3 Data May Change

The ESSENCE trial (NCT04822181) is a phase 3, randomized, double-blind study evaluating semaglutide 2.4 mg once weekly versus placebo in patients with biopsy-confirmed MASH and fibrosis stage F2 or F3 [18]. This is the trial designed to answer the exact question that the phase 2 study left open: does the Wegovy-equivalent dose improve both NASH resolution and fibrosis?

Novo Nordisk announced in 2024 that ESSENCE met its co-primary endpoints of MASH resolution without worsening of fibrosis and improvement in fibrosis without worsening of MASH at 72 weeks [19]. Full peer-reviewed results and the detailed safety profile have not yet been published. If the complete data confirm both endpoints with an acceptable risk profile, Novo Nordisk is expected to pursue a supplemental indication for MASH.

Until that approval exists, prescribing Wegovy for NASH remains off-label. Positive topline results are encouraging but not equivalent to regulatory review, which examines subgroup analyses, long-term safety, and risk-benefit across the full enrolled population.

Who Might Reasonably Consider Off-Label Use Now

Not every NASH patient is an appropriate candidate. Clinicians weigh several factors when considering off-label semaglutide for NASH.

Patients most likely to benefit have NASH with concurrent obesity (BMI ≥30) or type 2 diabetes, since the drug addresses multiple conditions simultaneously and may qualify for insurance coverage under an approved indication. The AASLD guidance supports considering GLP-1 RAs in this overlap population [10]. The expected weight loss of 10% to 15% with semaglutide 2.4 mg exceeds the 7% to 10% threshold associated with NASH histological improvement in observational data [2].

Patients who should approach with more caution include those with lean NASH (BMI <25), compensated cirrhosis (F4 fibrosis, which was excluded from the phase 2 trial), a personal history of medullary thyroid carcinoma or MEN2 syndrome (a contraindication per the Wegovy label), or a history of pancreatitis [8].

A reasonable clinical framework: if the patient qualifies for Wegovy under its approved weight management indication and has biopsy-confirmed or imaging-diagnosed NASH, the off-label liver benefit becomes a secondary rationale supporting an already-indicated prescription. If the patient does not independently qualify for weight management, the off-label case is weaker, the insurance pathway is closed, and the evidence base is thinner for their specific phenotype.

Monitoring and Follow-Up for Off-Label NASH Use

Patients using Wegovy off-label for NASH need structured monitoring beyond what the standard weight management protocol requires. Liver-specific follow-up should include alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at baseline and every 3 to 6 months. Noninvasive fibrosis assessments, either FIB-4 index or vibration-controlled transient elastography (FibroScan), should be performed at baseline and annually [10].

A baseline liver biopsy is the gold standard for confirming NASH but is not practical for all patients. The AASLD recommends biopsy when the diagnosis is uncertain or when it will change management [10]. If a patient initiates semaglutide specifically for presumed NASH, histological confirmation strengthens the clinical rationale.

GI symptoms should be tracked systematically during dose escalation. Body composition monitoring (lean mass versus fat mass) is advisable, particularly in patients with BMI <30, to detect disproportionate muscle loss. Lipase and amylase levels are not routinely recommended for screening but should be checked promptly if symptoms suggestive of pancreatitis develop.

Gallbladder ultrasound at baseline is reasonable in patients with known risk factors for cholelithiasis, given the increased gallstone risk during rapid weight loss [12]. Patients should be counseled to report right upper quadrant pain promptly.

The minimum treatment duration needed to assess liver response is approximately 48 to 72 weeks, based on the phase 2 trial timeline [6]. Clinicians and patients should agree on a defined reassessment window rather than continuing indefinitely without evaluating hepatic outcomes.